Upload Avatar (500 x 500)
Hai-Liang Hu
Medical School
Southern University of Science and Technology
Guangdong
Language: English, Chinese
Dna Repair
Tumor Metabolism
Targeted Therapy
Prostate Cancer
Hormone Therapy Resistance
Neuroendocrine Carcinoma
Non-Coding Rna
Tumor Migration
Hipsc
Neurodegenerative Diseases
Areas of Focus
- DNA damage and repair, tumor metabolism and targeted therapy
- Prostate cancer hormone therapy resistance and neuroendocrine small cell carcinoma
- Role of non-coding RNA in tumor occurrence, growth, and migration
- Development of human induced pluripotent stem cells (hiPSC) for studying neurodegenerative rare diseases
Work Experience
- 2001-2007 Postdoctoral Researcher: UCLA School of Medicine
- 2007-2012 Assistant Researcher: UCLA School of Medicine
- 2012-2016 Research Assistant Professor: UCLA School of Medicine
- 2016-2020 Assistant Professor: Duke University School of Medicine
- 2020- Associate Professor, Associate Researcher: Southern University of Science and Technology School of Medicine
Academic Background & Achievements
- 1991-1995 Bachelor of Science in Chemistry: Nankai University
- 1995-2000 Doctor of Science in Biochemistry and Molecular Biology: Shanghai Institute of Biochemistry, Chinese Academy of Sciences
- Doctoral Supervisor: Academician Hong Guofan
- Received the Excellent Doctoral Student P&G Award
Publications
- An Isoform switch of glutaminase drives therapeutic resistance and disease progression of prostate cancer, Hu H*, Huang J*, 2020
- N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway, Hu H*, Huang J*, 2019
- ATM deficiency promotes progression of castration resistant prostate cancer by enhancing Warburg effect, Hu H*, Huang J*, 2019
- ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response, Hu H*, 2013
- SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs, Hu H*, Lowry WE*, 2013
- MicroRNAs: new players in the DNA damage response, Hu H*, 2011
- ATM is down-regulated by N-Myc-regulated microRNA-421, Hu H*, 2010
- New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals, Hu H, 2008
- Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration, Hu H, 2008
- RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration, Hu H, 2005
- In Rhizobium leguminosarum, NodD represses its own transcription by competing with RNA polymerase for binding sites, Hu H, 2000
Awards
- 2019 DoD Prostate Cancer Research Program (PCRP) Fund Review Expert
- 2018 PCF Valor Challenge Award
- 2011 California Breast Cancer Research Program (BCRP) Young Investigator Award
- 2003 UCLA JCCF Postdoctoral Research Fellowship Award
- 2000 Chinese Academy of Sciences Excellent Doctoral P&G Award
